2190 — Zylox-Tonbridge Medical Technology Co Cashflow Statement
0.000.00%
Last trade - 00:00- HK$6.09bn
- HK$4.52bn
- CNY527.75m
- 35
- 12
- 48
- 18
Annual cashflow statement for Zylox-Tonbridge Medical Technology Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -66.6 | -100 | -200 | -114 | — |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 5.74 | 22.4 | 55.9 | -5.84 | — |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.75 | -13.9 | 14.2 | 1.8 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -53.1 | -82.3 | -116 | -91.3 | — |
| Capital Expenditures | -41.6 | -45.1 | -89.6 | -145 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -49 | -204 | -1,239 | 50.2 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -90.6 | -249 | -1,328 | -95 | — |
| Financing Cash Flow Items | 179 | 336 | 399 | -0.722 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 179 | 346 | 2,810 | -30.3 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 35.6 | 13.4 | 1,359 | -213 | — |